Organon (OGN -12.88%), a pharmaceutical company focused on women's health, biosimilars, and established brands, released its fiscal Q2 2025 (ended June 30, 2025) results on August 5, 2025. The company reported GAAP revenue of $1.59 billion, above analyst expectations of$1.552 billion, and non-GAAP adjusted earnings per share (EPS) of $1.00, exceeding the$0.95 consensus estimate (non-GAAP). Despite these beats, both revenue and earnings (GAAP and non-GAAP) declined compared to fiscal Q2 2024, with net inco ...